The results indicated that Huaier use was associated with lower mortality risk for the following subgroups of patients: aged ≤50 years, aged ≥50 years, males, smokers and non-smokers, alcohol users and non-users, without diabetes, MELD score ≥10 or <10, ALT ≥40 U/L or <40 U/L, AST ≥40 U/L or <40 U/L, TBIL ≥18.8 μmol/L or <18.8 μmol/L, γ-GGT ≥60 U/L or <60 U/L, PLT ≥100 × 109/L or <100 × 109/L, and those who underwent resection or minimally invasive or palliative treatments (all HR < 1.0). Here, GPT is linked to diabetes mellitus.